GBLX - GB Sciences, Inc.
| Previous Close | 0.1052 |
| Open | 0.1100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1015 - 0.1180 |
| 52 Week Range | 0.0800 - 0.4400 |
| Volume | 408,685 |
| Avg. Volume | 548,252 |
| Market Cap | 26.553M |
| Beta (3Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1050 |
| Earnings Date | Aug 15, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.
- PR Newswire
History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
BATON ROUGE, La., Aug. 6, 2019 /PRNewswire/ -- GB Sciences Louisiana (GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified patients in the state's nine licensed pharmacies. This is the first time that qualified patients have legal cannabis medicine available under Louisiana law, marking a historic turning point for patients, advocates, and regulators. "This is a watershed moment for our company and the State of Louisiana, reflecting many years of research and development by GB Sciences into the cannabis plant's biopharmaceutical applications," said John Davis, President of GB Sciences Louisiana.
- PR Newswire
GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars. LAS VEGAS, July 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), through its subsidiary, GBS Global Biopharma, Inc. ("GBS", Ottawa, CANADA), has filed a novel patent application to protect proprietary formulations for chronic pain based on new molecular docking simulations and functional assay data. New pain treatments are a vitally important area of research and development given the widespread rates of addiction and mortality tied to opioids.
CNW GroupGB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
- PR Newswire
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development.
- PR Newswire
GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water ...
- PR Newswire
GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation operations at LSU Agricultural Center are now open. This will allow a continuous harvest for patients by increasing GB Sciences Louisiana's production capacity 500%.
- PR Newswire
Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at 4:40pm. Learn more here.
- PR Newswire
GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between January 2016 and June 2017-- despite nearly 400 different "strain names" appearing on product packaging. Co-authored by GB Sciences, Chaminade University, Makai Biotechnology and Digipath Labs, and published in the journal Cannabis and Cannabinoid Research, the study reveals extremely low chemical diversity within the cannabis varieties sold in the Nevada market during its medical-only phase.
- PR Newswire
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 26, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.
- PR Newswire
Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 22, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.
- PR Newswire
GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /PRNewswire/ ...
- PR Newswire
GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS , March 12, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center ...
- Market Exclusive
GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center
In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.
- PR Newswire
GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium
On November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products. LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the success of its first annual, "Innovation in Medical Cannabis Therapies" (IMCT) Symposium, held on Friday, November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.
- PR Newswire
GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars
LAS VEGAS, Dec. 12, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their first crop in the rapidly expanding hemp market expects to yield a gross profit of $0.7million dollars as well as seeds and genetics. These seeds and genetic information will provide the mother plants in order to expand the program, which should prove to be a significant revenue generator for the Company. An integral part of the Company's success is its partnership with The Colorado Hemp Project (CHP). "GB Sciences told us what they wanted out of the plants, and we worked together to fill in the blanks," remarked Wild Bill.
- PR Newswire
Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit
Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia". LAS ...
- PR Newswire
GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases
LAS VEGAS, Dec. 7, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC. The Master Research and Development Agreement comes from the parties' desire to participate in joint research and development projects arising out of the production of therapeutic cannabis in Louisiana. As a public institution of higher education, the LSU AgCenter's public-private partnership with GB Sciences Louisiana represents a first in the therapeutic cannabis industry.
- PR Newswire
GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor
Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, Nov. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai Biotechnology, LLC, Dr. Alexander Stokes, and researchers from the University of Kyoto, Japan.
- PR Newswire
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
LAS VEGAS, Nov. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain. "We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain," said Dr. Andrea Small-Howard.